The Lancet, 2026 Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet What happens if we control the diet after as well thats what I wonder, like no UPFs whole food and plenty of fibre - these drugs are literally miracle workers but if we cant reeducate and change peoples relationship with food, including access to whole foods and plenty of fibre, is it that surprising a finding
In the same study, elevations in PGC-1 were found upon GLP-1 treatment of hepatic cells
UK regulatory data from the MHRA and EMA have not highlighted cognitive impairment as a safety concern for this medication class
To draw 40 units, you pull the plunger back until the top edge of the rubber plunger (the edge closest to the needle) aligns with the "40" marking on the barrel
Ruling out other causes of amenorrheasuch as thyroid dysfunction or nutritional deficiencyis important
Research Director, Docent Markku Lhteenvuo from the University of Eastern Finland, said: Because this is a registry-based study, we cannot determine exactly why or how these medications affect mood symptoms, but the association was quite strong
